Eric J. Chow, MM, MPH
Department of Pediatrics
FHRC, Clinical Research & Public Health Sciences Division
Medical Director, Cancer Survivor Program, Seattle Children's Hospital
With the increased use of multimodal therapy, there is an increasing number of long-term cancer survivors. At the same time, more intense therapies may be contributing to an increased burden of subsequent late effects among survivors compared with the non-cancer population, including cardiovascular disease. However, while state and national registries provide detailed and accurate estimates of cancer incidence, it has been much more challenging to study complications of cancer treatment. In this presentation, using childhood cancer survivors and recipients of hematopoietic cell transplantation as examples, we will provide an overview of various study designs and approaches to address this question, as well as how such data may be applied to building clinically relevant prediction models. The methods reviewed may also be applied to other disease states and populations.
About the speaker
Eric Chow, MD, MPH, is a pediatric oncologist and epidemiologist, with previous training from Yale University (BS), the University of California, San Francisco (MD), and the University of California, Berkeley (MPH). Since 2001, he has been at the University of Washington and the Fred Hutchinson Cancer Research Center, first as a pediatric resident, and subsequently as a pediatric hematology-oncology fellow and postdoctoral fellow in Epidemiology. Dr. Chow is currently as an Assistant Professor in Pediatrics and an Assistant Member at the FHCRC (Public Health Sciences and Clinical Research Divisions). He also serves as the medical director of the cancer survivor program at Seattle Children’s Hospital. Dr. Chow’s clinical and research focus is on cancer survivorship, with the goal to improve the care of all people who have had cancer through well-designed and detailed follow-up studies. His current projects involve analysis of long-term bone marrow transplant survivors to determine the influence of both treatment, host (genetic), and lifestyle factors in influencing subsequent risk of heart disease, and a new national study examining the efficacy of a chemopreventative strategy in reducing long-term heart injury in childhood cancer survivors.